Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, and melanoma. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TOCA
CUSIPN/A
Phone858-412-8400
Debt
Debt-to-Equity Ratio0.03
Current Ratio4.56
Quick Ratio4.56
Price-To-Earnings
Trailing P/E Ratio-3.53
Forward P/E Ratio-4.53
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales4,668.90
Cash FlowN/A
Price / CashN/A
Book Value$3.59 per share
Price / Book2.61
Profitability
EPS (Most Recent Fiscal Year)($2.66)
Net Income$-38,920,000.00
Net Margins-109,579.49%
Return on Equity-57.09%
Return on Assets-44.55%
Miscellaneous
Employees67
Outstanding Shares19,910,000
Market Cap$186.77
Tocagen (NASDAQ:TOCA) Frequently Asked Questions
What is Tocagen's stock symbol?
Tocagen trades on the NASDAQ under the ticker symbol "TOCA."
How were Tocagen's earnings last quarter?
Tocagen Inc (NASDAQ:TOCA) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.65) EPS for the quarter. The business had revenue of $0.01 million for the quarter. Tocagen had a negative return on equity of 57.09% and a negative net margin of 109,579.49%. View Tocagen's Earnings History.
When is Tocagen's next earnings date?
What price target have analysts set for TOCA?
4 equities research analysts have issued 12-month price objectives for Tocagen's stock. Their predictions range from $14.50 to $24.00. On average, they anticipate Tocagen's stock price to reach $18.3750 in the next twelve months. This suggests a possible upside of 95.9% from the stock's current price. View Analyst Ratings for Tocagen.
What is the consensus analysts' recommendation for Tocagen?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Tocagen's key competitors?
Some companies that are related to Tocagen include NuCana (NCNA), Adamas Pharmaceuticals (ADMS), CymaBay Therapeutics (CBAY), GlycoMimetics (GLYC), Dova Pharmaceuticals (DOVA), Abeona Therapeutics (ABEO), Collegium Pharmaceutical (COLL), Vectura Group (VEGPF), Viking Therapeutics (VKTX), Dicerna Pharmaceuticals (DRNA), Kura Oncology (KURA), Aptinyx (APTX), Urogen Pharma (URGN), Arbutus Biopharma (ABUS) and Odonate Therapeutics (ODT).
Who are Tocagen's key executives?
Tocagen's management team includes the folowing people:
- Mr. Martin J. Duvall, CEO & Director (Age 56)
- Mr. Thomas E. Darcy, Co-Founder & Director (Age 67)
- Mr. Mark G. Foletta CPA, Exec. VP & CFO (Age 57)
- Dr. Asha Das, Sr. VP & Chief Medical Officer (Age 53)
- Dr. Harry E. Gruber, Co-Founder, Pres of Science & Innovation and Director (Age 65)
When did Tocagen IPO?
(TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.
Has Tocagen been receiving favorable news coverage?
News coverage about TOCA stock has been trending somewhat positive on Sunday, Accern reports. The research group identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tocagen earned a media sentiment score of 0.12 on Accern's scale. They also assigned news articles about the company an impact score of 44.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Tocagen's major shareholders?
Tocagen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Pure Financial Advisors Inc. (0.40%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.
Which institutional investors are selling Tocagen stock?
How do I buy shares of Tocagen?
Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tocagen's stock price today?
One share of TOCA stock can currently be purchased for approximately $9.38.
How big of a company is Tocagen?
Tocagen has a market capitalization of $186.77 million and generates $40,000.00 in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Tocagen employs 67 workers across the globe.
How can I contact Tocagen?
Tocagen's mailing address is 3030 BUNKER HILL STREET SUITE 230, SAN DIEGO CA, 92109. The company can be reached via phone at 858-412-8400 or via email at [email protected]
MarketBeat Community Rating for Tocagen (NASDAQ TOCA)
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
